Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Friday, April 18, 2025, on account of Good Friday.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Marksans Pharma Limited Share Price

₹ 211.44 -2.08 (-0.97%)

Apr 17 2025 03:30 PM Pharmaceuticals NSE: MARKSANS

Marksans Pharma Limited Share Price Update

As of the latest trading session, Marksans Pharma Limited share price is currently at 211.44, which is down by -2.08 from its previous closing. Today, the stock has fluctuated between 209.68 and 214.83. Over the past year, Marksans Pharma Limited has achieved a return of 24.04 %. In the last month alone, the return has been 10.68 %. Read More...

Marksans Pharma Limited Performance

Day Range

Low209.68 High214.83

211.44

52 Week Range

Low 130.00 High 358.70

211.44

Marksans Pharma Limited Share Price

10579

524404

MARKSANS

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

213.52 Prev. Close

213.52 Volume (Shares)

609173.00

Total traded value

1288.03

Upper Circuit

256.22 Lower Circuit

170.81

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Marksans Pharma Limited Fundamentals

(Standalone)

Market Cap (Cr)	9581.69
PE Ratio (TTM)	52.30
Book Value / Share	28.48
Beta	1.29

ROE	11.46%
EPS (TTM)	4.05
Dividend Yield	0.28%
Net Profit Qtr (Cr)	55.46

Marksans Pharma Limited Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	311.87
Operating Expense	259.65
Net Profit	55.46
Net Profit Margin (%)	17.78
Earnings Per Share (EPS)	1.22
EBITDA	82.44
Effective Tax Rate (%)	25.77

Particulars	SEP 2024 (Values in Cr)
Revenue	308.63
Operating Expense	263.65
Net Profit	63.20
Net Profit Margin (%)	20.47
Earnings Per Share (EPS)	1.39
EBITDA	83.64
Effective Tax Rate (%)	17.19

Particulars	JUN 2024 (Values in Cr)
Revenue	254.53
Operating Expense	220.38
Net Profit	32.02
Net Profit Margin (%)	12.58
Earnings Per Share (EPS)	0.71
EBITDA	49.42
Effective Tax Rate (%)	24.30

Particulars	MAR 2024 (Values in Cr)
Revenue	225.20
Operating Expense	198.98
Net Profit	32.99
Net Profit Margin (%)	14.64
Earnings Per Share (EPS)	0.73
EBITDA	46.09
Effective Tax Rate (%)	14.08

Particulars	DEC 2023 (Values in Cr)
Revenue	241.36
Operating Expense	208.09
Net Profit	25.29
Net Profit Margin (%)	10.47
Earnings Per Share (EPS)	0.56
EBITDA	43.30
Effective Tax Rate (%)	26.90

Particulars	MAR 2024 (Values in Cr)
Revenue	853.27
Operating Expense	743.46
Net Profit	133.76
Net Profit Margin (%)	15.67
Earnings Per Share (EPS)	2.95
EBITDA	202.01
Effective Tax Rate (%)	22.18

Particulars	MAR 2023 (Values in Cr)
Revenue	655.20
Operating Expense	583.65
Net Profit	102.87
Net Profit Margin (%)	15.70
Earnings Per Share (EPS)	2.48
EBITDA	152.39
Effective Tax Rate (%)	22.09

Particulars	MAR 2022 (Values in Cr)
Revenue	658.29
Operating Expense	566.04
Net Profit	103.99
Net Profit Margin (%)	15.79
Earnings Per Share (EPS)	2.54
EBITDA	155.97
Effective Tax Rate (%)	22.68

Particulars	MAR 2021 (Values in Cr)
Revenue	599.55
Operating Expense	506.38
Net Profit	98.38
Net Profit Margin (%)	16.40
Earnings Per Share (EPS)	2.40
EBITDA	144.87
Effective Tax Rate (%)	20.87

Particulars	MAR 2020 (Values in Cr)
Revenue	433.42
Operating Expense	380.86
Net Profit	37.90
Net Profit Margin (%)	8.74
Earnings Per Share (EPS)	0.93
EBITDA	71.66
Effective Tax Rate (%)	28.10

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	45.57
ROE %	16.53
ROCE %	20.78
Total Debt to Total Equity	0.10
EBITDA Margin	23.38

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	38.51
ROE %	18.00
ROCE %	21.77
Total Debt to Total Equity	0.08
EBITDA Margin	21.52

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	27.10
ROE %	17.89
ROCE %	22.83
Total Debt to Total Equity	0.07
EBITDA Margin	20.17

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	21.66
ROE %	31.34
ROCE %	38.77
Total Debt to Total Equity	0.04
EBITDA Margin	25.16

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	15.54
ROE %	20.49
ROCE %	25.02
Total Debt to Total Equity	0.11
EBITDA Margin	16.98

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	26.98
ROE %	11.46
ROCE %	14.67
Total Debt to Total Equity	0.01
EBITDA Margin	23.67

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	24.52
ROE %	10.85
ROCE %	14.11
Total Debt to Total Equity	0.01
EBITDA Margin	23.26

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	16.90
ROE %	15.02
ROCE %	19.45
Total Debt to Total Equity	0.02
EBITDA Margin	23.69

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	14.65
ROE %	17.29
ROCE %	22.04
Total Debt to Total Equity	0.02
EBITDA Margin	24.16

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	12.35
ROE %	7.07
ROCE %	10.19
Total Debt to Total Equity	0.09
EBITDA Margin	16.53

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	673.57
Total Assets	2680.95
Total Liabilities	2680.95
Total Equity	2085.90
Share Outstanding	453163746
Price to Book Ratio	5.62
Return on Assets (%)	11.70
Return on Capital (%)	14.83

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	714.96
Total Assets	2190.38
Total Liabilities	2190.38
Total Equity	1765.07
Share Outstanding	453163746
Price to Book Ratio	2.87
Return on Assets (%)	12.15
Return on Capital (%)	14.74

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	349.26
Total Assets	1640.10
Total Liabilities	1640.10
Total Equity	1222.97
Share Outstanding	409313698
Price to Book Ratio	2.70
Return on Assets (%)	11.25
Return on Capital (%)	14.6

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	212.18
Total Assets	1228.81
Total Liabilities	1228.81
Total Equity	905.35
Share Outstanding	409313698
Price to Book Ratio	3.41
Return on Assets (%)	19.20
Return on Capital (%)	25.53

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	93.72
Total Assets	902.66
Total Liabilities	902.66
Total Equity	649.12
Share Outstanding	409313698
Price to Book Ratio	1.13
Return on Assets (%)	13.37
Return on Capital (%)	18.08

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	312.22
Total Assets	1516.03
Total Liabilities	1516.03
Total Equity	1222.70
Share Outstanding	453163746
Price to Book Ratio	5.62
Return on Assets (%)	8.82
Return on Capital (%)	10.94

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	440.26
Total Assets	1344.86
Total Liabilities	1344.86
Total Equity	1111.32
Share Outstanding	453163746
Price to Book Ratio	2.87
Return on Assets (%)	7.64
Return on Capital (%)	9.26

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	224.04
Total Assets	965.60
Total Liabilities	965.60
Total Equity	784.67
Share Outstanding	409313698
Price to Book Ratio	2.70
Return on Assets (%)	10.76
Return on Capital (%)	13.17

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	105.61
Total Assets	740.69
Total Liabilities	740.69
Total Equity	599.71
Share Outstanding	409313698
Price to Book Ratio	3.41
Return on Assets (%)	13.28
Return on Capital (%)	16.4

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	3.35
Total Assets	599.78
Total Liabilities	599.78
Total Equity	505.62
Share Outstanding	409313698
Price to Book Ratio	1.13
Return on Assets (%)	6.31
Return on Capital (%)	7.5

Particulars	MAR 2024 (Values in Cr)
Net Income	423.52
Cash from Operations	352.75
Cash from Investing	-140.84
Cash from Financing	-68.72
Net change in Cash	20.84
Free Cash Flow	561.59

Particulars	MAR 2023 (Values in Cr)
Net Income	337.65
Cash from Operations	300.42
Cash from Investing	-259.21
Cash from Financing	197.82
Net change in Cash	176.02
Free Cash Flow	354.05

Particulars	MAR 2022 (Values in Cr)
Net Income	247.51
Cash from Operations	172.11
Cash from Investing	-84.39
Cash from Financing	79.51
Net change in Cash	94.37
Free Cash Flow	218.44

Particulars	MAR 2021 (Values in Cr)
Net Income	302.16
Cash from Operations	227.12
Cash from Investing	-44.84
Cash from Financing	-15.28
Net change in Cash	118.45
Free Cash Flow	273.54

Particulars	MAR 2020 (Values in Cr)
Net Income	157.17
Cash from Operations	258.32
Cash from Investing	-59.58
Cash from Financing	-113.55
Net change in Cash	60.18
Free Cash Flow	318.23

Particulars	MAR 2024 (Values in Cr)
Net Income	171.89
Cash from Operations	72.81
Cash from Investing	-114.22
Cash from Financing	-26.21
Net change in Cash	-106.38
Free Cash Flow	228.48

Particulars	MAR 2023 (Values in Cr)
Net Income	132.03
Cash from Operations	83.34
Cash from Investing	-194.62
Cash from Financing	210.01
Net change in Cash	67.12
Free Cash Flow	118.62

Particulars	MAR 2022 (Values in Cr)
Net Income	134.50
Cash from Operations	87.80
Cash from Investing	-128.06
Cash from Financing	70.86
Net change in Cash	-1.23
Free Cash Flow	110.65

Particulars	MAR 2021 (Values in Cr)
Net Income	124.33
Cash from Operations	127.13
Cash from Investing	8.87
Cash from Financing	-13.53
Net change in Cash	102.26
Free Cash Flow	148.13

Particulars	MAR 2020 (Values in Cr)
Net Income	52.72
Cash from Operations	118.06
Cash from Investing	-24.14
Cash from Financing	-81.87
Net change in Cash	1.55
Free Cash Flow	142.47

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L	39.16	21.05	2.13	300.10	34.11 / 77.70
BLISS GVS PHARMA LTD	124.90	16.37	1.30	1316.07	92.25 / 184.95
CIPLA LTD	1515.45	24.53	4.31	122390.34	1310.05 / 1702.00
FERMENTA BIOTECH LIMITED	274.60	22.75	2.78	808.17	145.00 / 449.00

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L	39.16	23.59	6.65	300.10	34.11 / 77.70
AMRUTAJAN HEALTH LTD	674.85	39.56	6.55	1951.03	548.05 / 861.40
ASTRAZENECA PHARMA IND LT	8749.25	130.49	32.19	21873.13	5000.00 / 9101.00
BLISS GVS PHARMA LTD	124.90	16.22	1.28	1316.07	92.25 / 184.95

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 210.00
26 Days 214.10
10 Days 210.50
50 Days 224.10
12 Days 210.90
100 Days 238.90
20 Days 212.40
200 Days 235.50

213.51
PIVOT

First Resistance	216.01
Second Resistance	218.50
Third Resistance	221.00

First Support	211.02
Second Support	208.52
Third Support	206.03

RSI	48.44
MACD	-3.24
Commodity Channel Index (CCI)	-17.83

ADX	18.15
Williams % R	-46.64

Marksans Pharma Limited Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

29.36 Promoter Holdings

43.87 FII

22.2 DII

4.55 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Mark Saldanha	Shareholding of Promoter and Promoter Group	1.98491553E8	43.8
Orbimed Asia Iv Mauritius Fvci Limited	Public Shareholding	4.9324324E7	10.88
Massachusetts Institute Of Technology	Public Shareholding	1.05E7	2.32
Uti-healthcare Fund	Public Shareholding	6393593.0	1.41
Kotak Mahindra Trustee Co Ltd A/c Kotak Special Opportunities Fund	Public Shareholding	4777836.0	1.05
Sandra Saldanha	Shareholding of Promoter and Promoter Group	330456.0	0.07

Marksans Pharma Limited

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
2023-06-07	0.5	Final	2023-06-07	Equity shares	2022-08-19	0.25	Final	2022-08-23	Equity shares	2021-09-15	0.25	Final	2021-09-17	Equity shares	2020-09-22	0.1	Final	2020-09-24	Equity shares	2019-09-19	0.05	Final	2019-09-21	Equity shares	2018-09-19	0.05	Final	2018-09-22	Equity shares	2017-09-19	0.05	Final	2017-09-21	Equity shares	2016-09-22	0.12	Final	2016-09-24	Equity shares	2015-09-23	0.12	Final	2015-09-26	Equity shares	2014-09-18	0.1	Final	2014-09-20	Equity shares

Marksans Pharma Share Result Highlights

Particulars	Sep 2024 (₹ in Cr)	Jun 2024 (₹ in Cr)	Mar 2024 (₹ in Cr)	Dec 2023 (₹ in Cr)	Sep 2023 (₹ in Cr)
Revenue	308.63	254.53	225.20	241.36	204.67
Operating Expense	263.65	220.38	198.98	208.09	176.10
Net Profit	63.20	32.02	32.99	25.29	31.29
Net Profit Margin (%)	20.47	12.58	14.64	10.47	15.28
Earnings Per Share (₹)	1.39	0.71	0.73	0.56	0.69
EBITDA	83.64	49.42	46.09	43.30	53.23
Effective Tax Rate (%)	17.19	24.30	14.08	26.90	29.68

Key Highlights:

Revenue Growth: Revenue grew significantly in Sep 2024 to ₹308.63 Cr from ₹204.67 Cr in Sep 2023.
Strong Profit Performance: Net profit increased to ₹63.20 Cr with a 20.47% margin.
Earnings Per Share (EPS): The EPS surged to ₹1.39 in Sep 2024.
Operating Efficiency: Operating expenses grew slower than revenue, improving margins.
The Marksans Pharma share price has shown positive results, reflecting the growth in key financial metrics.

Marksans Pharma Share Annual Reports

Particulars	Mar 2024 (₹ in Cr)	Mar 2023 (₹ in Cr)
Revenue	853.27	732.00
Operating Expense	743.46	650.23
Net Profit	133.76	112.65
Net Profit Margin (%)	15.67	15.39
Earnings Per Share (₹)	2.95	2.50
EBITDA	202.01	180.52
Effective Tax Rate (%)	22.18	20.50

Key Highlights:

Revenue Growth: Revenue increased by approximately ₹121.27 Cr from ₹732.00 Cr in FY 2022-23.
Profitability: The net profit grew to ₹133.76 Cr in FY 2023-24 with a 15.67% margin.
Strong EPS Performance: Earnings per share rose to ₹2.95.
Operational Efficiency: EBITDA grew by ₹21.49 Cr, reflecting improved operational efficiency.
The annual financial performance has had a positive impact on the Marksans Pharma share price, reflecting steady growth in revenue and profits.

Marksans Pharma Share Dividend

Particulars	Ex-Date	Record Date
Dividend per Share (₹)	07 Jun, 2023	07 Jun, 2023
Dividend Yield (%)	0.5	Equity Shares

Key Highlights:

Consistent Payouts: Marksans Pharma has regularly paid dividends, with the latest payout of ₹0.5 per share in June 2023.
Shareholder Returns: Dividend yields have been consistent, offering moderate returns to shareholders.
Final Dividends: Recent payouts have been final dividends, reflecting the company’s strong profit performance.
The dividend payouts complement the overall performance of the Marksans Pharma share price, providing additional value to investors.

About Marksans Pharma Limited

Learn More About Stocks

Zydus Lifesciences Invests in Feldan to Boost Drug Delivery Innovation

Zydus Lifesciences’ VC arm Zynext Ventures invests in Canada’s Feldan Therapeutics to advance innovation in intracellular drug delivery technologies.

17 Apr, 2025 | 3 Min. read

DLF To Sell Kolkata IT SEZ To Srijan Group For Rs.693 Crore

DLF Ltd to sell its 25.9-acre Kolkata IT SEZ, including DLF Tech Park, to Srijan Group for Rs.693 crore through a slump sale.

17 Apr, 2025 | 3 Min. read

UltraTech Cement Acquires 26% Stake in Solar SPV for Rs.25.5 Crore

UltraTech Cement to invest Rs.25.5 crore for a 26% stake in AMPIN C&I Power Eight to secure green energy for operations and reduce power costs.

17 Apr, 2025 | 3 Min. read

BHEL Signs Tech Deal With BARC to Cut Green Hydrogen Costs

BHEL partners with BARC to adopt indigenous diaphragm technology for electrolysers, aiming to cut green hydrogen costs and reduce import dependency.

17 Apr, 2025 | 2 Min. read

CCI Approves Aster DM–Quality Care Merger; New Entity Named Aster DM Quality Care

CCI clears merger of Aster DM Healthcare and Quality Care India Ltd, forming Aster DM Quality Care Ltd. Combined entity to operate 38 hospitals with 10,150 beds.

16 Apr, 2025 | 3 Min. read

ICICI Lombard Q4 Profit Falls 1.9%, Declares ₹7 Final Dividend

ICICI Lombard Q4 net profit declines by 1.9% YoY to ₹509.6 crore, while FY25 PAT jumps 30.7%. Board declares ₹7 final dividend, total ₹12.5 for FY25.

16 Apr, 2025 | 3 Min. read

IndusInd Bank Finds ₹1,979 Crore Net Worth Hit in Derivatives Audit

An external audit reveals ₹1,979 crore impact on IndusInd Bank’s net worth due to derivative discrepancies. Bank to reflect changes in FY25 financial reports.

16 Apr, 2025 | 2 Min. read

Oil India Wins 9 Blocks in OALP Round-IX, Acreage Jumps 85%

Oil India secures 9 exploration blocks in OALP Round-IX, expanding its acreage by 85% to 1.10 lakh sq km. ONGC, Cairn, and BP also win key bids.

16 Apr, 2025 | 3 Min. read

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

We have something for everyone

Explore More Investment Options

Start Investing

Stocks

Secure and enhance your financial future today

Invest

IPOs

Your gateway to future financial opportunities

Invest

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x

Invest

US Stocks

Discover opportunities to invest in elite FAANG stocks

Invest

Frequently Asked Questions

What is the Share Price of Marksans Pharma Ltd?

Answer Field: The share price of Marksans Pharma Ltd for NSE is ₹ 211.44 and for BSE is ₹ 212.

What is the Market Cap of Marksans Pharma Ltd?

Answer Field: The market cap of Marksans Pharma Ltd for NSE is ₹ 95,81.69 Cr. and for BSE is ₹ 96,07.07 Cr. as of now.

What is the 52 Week High and Low of Marksans Pharma Ltd?

Answer Field: The 52 Week High and Low of Marksans Pharma Ltd for NSE is ₹ 358.70 and ₹ 130.00 and for BSE is ₹ 358.50 and ₹ 130.15.

How to Buy Marksans Pharma Ltd share?

Answer Field: You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Marksans Pharma Ltd?

Answer Field: The 1 year returns on the stock has been 24.04%.

What is the Current Share Price of Marksans Pharma Ltd?

Answer Field: Marksans Pharma Ltd share price is for NSE ₹ 211.44 & for BSE ₹ 212 as on Apr 17 2025 03:30 PM.

What is the Market Cap of Marksans Pharma Ltd Share?

Answer Field: The market cap of Marksans Pharma Ltd for NSE ₹ 95,81.69 & for BSE ₹ 96,07.07 as on Apr 17 2025 03:30 PM.

What is the P/E Ratio of Marksans Pharma Ltd Share?

Answer Field: As on Apr 17 2025 03:30 PM the price-to-earnings (PE) ratio for Marksans Pharma Ltd share is 52.30.

What is the PB ratio of Marksans Pharma Ltd Share?

Answer Field: As on Apr 17 2025 03:30 PM, the price-to-book (PB) ratio for Marksans Pharma Ltd share is 28.48.

How to Buy Marksans Pharma Ltd Share?

Answer Field: You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a demat accountopens in a new tab.

How to Buy Marksans Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Marksans Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Marksans Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Popular FAQs

Who is the CEO of Marksans Pharma Ltd?

Marksans Pharma Ltd is led by Mr. Mark Saldanha, who serves as the Managing Director and Chief Executive Officer of the company. Under his leadership, the company has expanded its presence in the global pharmaceutical market and achieved significant growth in various regions. Mr. Saldanha’s vision has been instrumental in driving the company’s strategic acquisitions, as well as in its research and development initiatives.

When was Marksans Pharma established?

Marksans Pharma Ltd was initially incorporated as Tasc Pharmaceuticals Limited in April 1982. Following a Scheme of Amalgamation, the company’s name was changed to Marksans Pharma Ltd on 10th October 2005. The rebranding marked the beginning of the company’s expanded focus on pharmaceutical formulations, and since then, it has become a prominent player in the pharmaceutical sector.

What factors influence the Marksans Pharma Share Price?

The Marksans Pharma share price is influenced by several key factors, including:

The company’s financial performance, including revenue growth, net profit, and earnings per share (EPS)
Acquisitions and R&D activities
Strong revenue and profit growth that boosts investor confidence
Successful product launches and US FDA approvals
Expanding R&D facilities
Broader pharmaceutical market trends and regulatory changes
Global economic factors impacting stock performance

Is Marksans Pharma debt-free?

Marksans Pharma Ltd is not entirely debt-free. However, the company has maintained a manageable level of debt as part of its capital structure. It strategically acquires businesses and invests in research and development to fuel its growth. The debt levels are often monitored to ensure they do not adversely impact the company's financial health. Despite this, the company has successfully maintained profitability and strong cash flow, helping it manage its liabilities efficiently.

What is the CAGR of Marksans Pharma Share?

The Marksans Pharma share price has demonstrated a Compound Annual Growth Rate (CAGR) of:

20% over the last 10 years
87% over the last 5 years
72% over the last 3 years
96% over the past year

This impressive growth rate highlights the company’s consistent performance and the market’s positive response to its strategic initiatives, including acquisitions and expanding its product portfolio.

How has the Marksans Pharma Share Price performed over the past year?

Over the past year, the Marksans Pharma share price has seen a remarkable increase of 96%. This surge in share price reflects strong financial performance, successful product approvals, and the company's continued expansion in both domestic and international markets. The robust growth in the past year has also been fueled by investor confidence, supported by strategic acquisitions such as Tevapharm India and the company's increasing presence in the global pharmaceutical industry.

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Scan to download

Download from App Store

Download from Play Store

9.5 lakh+ Users

4+ App Rating

4 Languages

₹4400+ Cr MTF Book

Open Demat Account

🚨 Trading Holiday 🚨

Open a Free Demat Account

Trade Now, Pay Later with up to 4x

Track Market Movers Instantly

Marksans Pharma Limited Share Price

Marksans Pharma Limited Share Price Update

Marksans Pharma Limited Performance

Day Range

52 Week Range

Marksans Pharma Limited Share Price

Open Price

213.52

Prev. Close

213.52

Volume (Shares)

609173.00

Total traded value

1288.03

Upper Circuit

256.22

Lower Circuit

170.81

Marksans Pharma Limited Fundamentals

Marksans Pharma Limited Financials

Revenue

Net income

Technicals

Over 1 Month

10.68

Over 3 Months

-19.15

Over 6 Months

-25.32

Over 1 Year

24.04

Over 3 Years

54.61

Over 5 Years

59.01

Marksans Pharma Limited Future

Future: Price

Discount/Premium

Active Calls

Active Puts

Marksans Pharma Limited Shareholding Pattern

Stock Holding

View Live Stock Screeners

Holding

Public

29.36

Promoter Holdings

43.87

FII

22.2

DII

4.55

Promoter Shares(Pledge Percentage)

0.0

Holding %

Pledges % of promoter shares %

MF Holding %

FII Holding %

Marksans Pharma Limited

Marksans Pharma Share Result Highlights

Marksans Pharma Share Annual Reports

Marksans Pharma Share Dividend

About Marksans Pharma Limited

Companies Owned by Marksans Pharma Limited

Learn More About Stocks

Zydus Lifesciences Invests in Feldan to Boost Drug Delivery Innovation

DLF To Sell Kolkata IT SEZ To Srijan Group For Rs.693 Crore

UltraTech Cement Acquires 26% Stake in Solar SPV for Rs.25.5 Crore

BHEL Signs Tech Deal With BARC to Cut Green Hydrogen Costs

Explore More Investment Options

Stocks

IPOs

MTF

US Stocks

Frequently Asked Questions

What is the Share Price of Marksans Pharma Ltd?